Cao Jingwen, Huang Wenlong
School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China.
Anticancer Drugs. 2017 Nov;28(10):1079-1085. doi: 10.1097/CAD.0000000000000559.
The Hippo pathway has generated considerable interest in recent years because of its involvement in several key hallmarks of cancer progression and metastasis. Research on the Hippo signaling pathway in cancer has been used to determine the activity of yes-associated protein (YAP) in tumorigenesis and disease progression. Previous studies have shown that the Hippo pathway can be used as a target to inhibit YAP activity and is a viable treatment for cancer. However, more studies are required to further advance our understanding of the Hippo signaling pathway in cancer. It has been shown that knockout of serine/threonine-kinases LATS1/2 in the Hippo pathway suppresses cancer immunity in mice. In addition, suppression of the oncogene YAP could contribute toward cancer immune therapy. Therefore, regulation of Hippo signaling can be an attractive alternative strategy for cancer treatment. This review will provide a summary of currently known compounds that activate or suppress the Hippo pathway.
近年来，由于河马通路（Hippo pathway）参与癌症进展和转移的几个关键特征，它引起了人们的极大兴趣。对癌症中河马信号通路的研究已被用于确定Yes相关蛋白（YAP）在肿瘤发生和疾病进展中的活性。先前的研究表明，河马通路可作为抑制YAP活性的靶点，是一种可行的癌症治疗方法。然而，需要更多的研究来进一步加深我们对癌症中河马信号通路的理解。研究表明，河马通路中丝氨酸/苏氨酸激酶LATS1/2的敲除会抑制小鼠的癌症免疫。此外，抑制癌基因YAP可能有助于癌症免疫治疗。因此，调节河马信号可能是一种有吸引力的癌症治疗替代策略。本综述将总结目前已知的激活或抑制河马通路的化合物。
